Seza Ozen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3539650/publications.pdf

Version: 2024-02-01

148 papers	6,557 citations	109321 35 h-index	74163 75 g-index
153 all docs	153 docs citations	153 times ranked	6245 citing authors

#	Article	IF	Citations
1	Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. Nature Genetics, 2016, 48, 67-73.	21.4	513
2	EULAR recommendations for the management of familial Mediterranean fever. Annals of the Rheumatic Diseases, 2016, 75, 644-651.	0.9	393
3	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 481-489.	0.9	338
4	Clinical Features, Treatment, and Outcome of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A Multinational, Multicenter Study of 362 Patients. Arthritis and Rheumatology, 2014, 66, 3160-3169.	5.6	322
5	Classification criteria for autoinflammatory recurrent fevers. Annals of the Rheumatic Diseases, 2019, 78, 1025-1032.	0.9	300
6	Mutation frequency of Familial Mediterranean Fever and evidence for a high carrier rate in the Turkish population. European Journal of Human Genetics, 2001, 9, 553-555.	2.8	273
7	Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. Annals of the Rheumatic Diseases, 2015, 74, 799-805.	0.9	215
8	Biallelic hypomorphic mutations in a linear deubiquitinase define otulipenia, an early-onset autoinflammatory disease. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 10127-10132.	7.1	206
9	Juvenile polyarteritis: Results of a multicenter survey of 110 children. Journal of Pediatrics, 2004, 145, 517-522.	1.8	196
10	A20 haploinsufficiency (HA20): clinical phenotypes and disease course of patients with a newly recognised NF-kB-mediated autoinflammatory disease. Annals of the Rheumatic Diseases, 2018, 77, 728-735.	0.9	176
11	MEFV mutations in Behï¿½et's disease. Human Mutation, 2000, 16, 271-272.	2.5	144
12	HLA-DRB1*11and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 15970-15975.	7.1	139
13	European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative. Annals of the Rheumatic Diseases, 2017, 76, 1788-1796.	0.9	139
14	Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS). Annals of the Rheumatic Diseases, 2013, 72, 1628-1633.	0.9	123
15	Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications. Annals of the Rheumatic Diseases, 2017, 76, 906-913.	0.9	123
16	European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. Annals of the Rheumatic Diseases, 2017, 76, 1965-1973.	0.9	105
17	European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease â€“ the SHARE initiative. Rheumatology, 2019, 58, 672-682.	1.9	103
18	Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature. Clinical Rheumatology, 2018, 37, 3329-3335.	2.2	97

#	Article	IF	Citations
19	Results from a multicentre international registry of familial Mediterranean fever: impact of environment on the expression of a monogenic disease in children. Annals of the Rheumatic Diseases, 2014, 73, 662-667.	0.9	92
20	Childhood vasculitides in Turkey: a nationwide survey. Clinical Rheumatology, 2006, 26, 196-200.	2.2	88
21	Vasculitis as an adverse event following immunization â€“ Systematic literature review. Vaccine, 2016, 34, 6641-6651.	3.8	87
22	Mutations in the gene for familial Mediterranean fever: do they predispose to inflammation?. Journal of Rheumatology, 2003, 30, 2014-8.	2.0	87
23	The changing face of polyarteritis nodosa and necrotizing vasculitis. Nature Reviews Rheumatology, 2017, 13, 381-386.	8.0	77
24	European consensus-based recommendations for the diagnosis and treatment of rare paediatric vasculitides â€“ the SHARE initiative. Rheumatology, 2019, 58, 656-671.	1.9	77
25	Development of the autoinflammatory disease damage index (ADDI). Annals of the Rheumatic Diseases, 2017, 76, 821-830.	0.9	68
26	Kawasaki-like disease in children with COVID-19. Rheumatology International, 2020, 40, 2105-2115.	3.0	67
27	Autoinflammatory Diseases with Periodic Fevers. Current Rheumatology Reports, 2017, 19, 41.	4.7	66
28	A Monogenic Disease with a Variety of Phenotypes: Deficiency of Adenosine Deaminase 2. Journal of Rheumatology, 2020, 47, 117-125.	2.0	65
29	Failure to thrive, interstitial lung disease, and progressive digital necrosis with onset in infancy. Journal of the American Academy of Dermatology, 2016, 74, 186-189.	1.2	64
30	Human TBK1 deficiency leads to autoinflammation driven by TNF-induced cell death. Cell, 2021, 184, 4447-4463.e20.	28.9	64
31	A web-based collection of genotype-phenotype associations in hereditary recurrent fevers from the Eurofever registry. Orphanet Journal of Rare Diseases, 2017, 12, 167.	2.7	52
32	Biological classification of childhood arthritis: roadmap to a molecular nomenclature. Nature Reviews Rheumatology, 2021, 17, 257-269.	8.0	52
33	Different histological classifications for Henoch-SchÃ¶nlein purpura nephritis: which one should be used?. Pediatric Rheumatology, 2019, 17, 10.	2.1	50
34	ISSAID/EMQN Best Practice Guidelines for the Genetic Diagnosis of Monogenic Autoinflammatory Diseases in the Next-Generation Sequencing Era. Clinical Chemistry, 2020, 66, 525-536.	3.2	43
35	Hematopoietic Cell Transplantation Cures Adenosine Deaminase 2 Deficiency: Report on 30 Patients. Journal of Clinical Immunology, 2021, 41, 1633-1647.	3.8	43
36	The Eurofever Project: towards better care for autoinflammatory diseases. European Journal of Pediatrics, 2011, 170, 445-452.	2.7	41

#	Article	IF	Citations
37	Spontaneous reports of vasculitis as an adverse event following immunization: A descriptive analysis across three international databases. Vaccine, 2016, 34, 6634-6640.	3.8	41
38	Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial. Annals of the Rheumatic Diseases, 2020, 79, 1362-1369.	0.9	39
39	The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist. Annals of the Rheumatic Diseases, 2022, 81, 907-921.	0.9	38
40	Whole Exome Sequencing in Early-onset Systemic Lupus Erythematosus. Journal of Rheumatology, 2018, 45, 1671-1679.	2.0	37
41	Implications of COVID-19 in pediatric rheumatology. Rheumatology International, 2020, 40, 1193-1213.	3.0	35
42	Differences and similarities of multisystem inflammatory syndrome in children, Kawasaki disease and macrophage activating syndrome due to systemic juvenile idiopathic arthritis: a comparative study. Rheumatology International, 2022, 42, 879-889.	3.0	35
43	The distribution of juvenile idiopathic arthritis in the eastern Mediterranean: results from the registry of the Turkish Paediatric Rheumatology Association. Clinical and Experimental Rheumatology, 2011, 29, 111-6.	0.8	35
44	Renal amyloidosis in familial Mediterranean fever. Kidney International, 2004, 65, 1118-1127.	5.2	34
45	What is the best acute phase reactant for familial Mediterranean fever follow-up and its role in the prediction of complications? A systematic review. Rheumatology International, 2016, 36, 483-487.	3.0	33
46	Efficacy and safety of treatments in Familial Mediterranean fever: a systematic review. Rheumatology International, 2016, 36, 325-331.	3.0	32
47	Towards a new set of classification criteria for PFAPA syndrome. Pediatric Rheumatology, 2018, 16, 60.	2.1	32
48	The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS. Annals of the Rheumatic Diseases, 2022, 81, 601-613.	0.9	31
49	Pediatric Vasculitis. Current Rheumatology Reports, 2012, 14, 121-129.	4.7	30
50	Comparing polyarteritis nodosa in children and adults: a single center study. International Journal of Rheumatic Diseases, 2017, 20, 1016-1022.	1.9	30
51	Defining colchicine resistance/intolerance in patients with familial Mediterranean fever: a modified-Delphi consensus approach. Rheumatology, 2021, 60, 3799-3808.	1.9	29
52	Multisystem inflammatory syndrome in children during the COVID-19 pandemic in Turkey: first report from the Eastern Mediterranean. Clinical Rheumatology, 2021, 40, 3227-3237.	2.2	29
53	Familial Mediterranean fever-related miR-197-3p targets IL1R1 gene and modulates inflammation in monocytes and synovial fibroblasts. Scientific Reports, 2021, 11, 685.	3.3	28
54	In silico validation of the Autoinflammatory Disease Damage Index. Annals of the Rheumatic Diseases, 2018, 77, 1599-1605.	0.9	27

#	Article	IF	Citations
55	Arg753Gln TLR-2 polymorphism in familial mediterranean fever: linking the environment to the phenotype in a monogenic inflammatory disease. Journal of Rheumatology, 2006, 33, 2498-500.	2.0	26
56	Human OTULIN haploinsufficiency impairs cell-intrinsic immunity to staphylococcal Î±-toxin. Science, 2022, 376, eabm6380.	12.6	25
57	Vasculitis in children. Nephrology Dialysis Transplantation, 2015, 30 Suppl 1, i94-103.	0.7	24
58	The difference of the inflammatory milieu in MIS-C and severe COVID-19. Pediatric Research, 2022, 92, 1805-1814.	2.3	24
59	COVID-19 associated pediatric vasculitis: A systematic review and detailed analysis of the pathogenesis. Seminars in Arthritis and Rheumatism, 2022, 55, 152047.	3.4	24
60	Pediatric onset BehÃ§et disease. Current Opinion in Rheumatology, 2010, 22, 585-589.	4.3	23
61	Update on the epidemiology and disease outcome of Familial Mediterranean fever. Best Practice and Research in Clinical Rheumatology, 2018, 32, 254-260.	3.3	23
62	The â€œotherâ€•vasculitis syndromes and kidney involvement. Pediatric Nephrology, 2010, 25, 1633-1639.	1.7	21
63	Endothelial function in patients with familial Mediterranean fever-related amyloidosis and association with cardiovascular events. Rheumatology, 2014, 53, 2002-2008.	1.9	21
64	Problems in classifying vasculitis in children. Pediatric Nephrology, 2005, 20, 1214-1218.	1.7	20
65	A clinical update on inflammasomopathies. International Immunology, 2017, 29, 393-400.	4.0	20
66	EPIC-TABSAT: analysis tool for targeted bisulfite sequencing experiments and array-based methylation studies. Nucleic Acids Research, 2019, 47, W166-W170.	14.5	19
67	Childhood systemic vasculitis. Best Practice and Research in Clinical Rheumatology, 2017, 31, 558-575.	3.3	18
68	A retrospective study comparing the phenotype and outcomes of patients with polyarteritis nodosa between UK and Turkish cohorts. Rheumatology International, 2018, 38, 1833-1840.	3.0	18
69	Vasculitis Pathogenesis: Can We Talk About Precision Medicine?. Frontiers in Immunology, 2018, 9, 1892.	4.8	18
70	Childhood vasculitis. Rheumatology, 2020, 59, iii95-iii100.	1.9	18
71	In vitro evaluation of effects of sustained anti-TNF release from MPEG-PCL-MPEG and PCL microspheres on human rheumatoid arthritis synoviocytes. Journal of Biomaterials Applications, 2014, 29, 524-542.	2.4	17
72	Etanercept treatment in five cases of refractory chronic recurrent multifocal osteomyelitis (CRMO). Joint Bone Spine, 2015, 82, 471-473.	1.6	16

#	Article	IF	Citations
73	An International Delphi Survey for the Definition of New Classification Criteria for Familial Mediterranean Fever, Mevalonate Kinase Deficiency, TNF Receptorâ€“associated Periodic Fever Syndromes, and Cryopyrin-associated Periodic Syndrome. Journal of Rheumatology, 2019, 46, 429-436.	2.0	16
74	Comparison of IVIG resistance predictive models in Kawasaki disease. Pediatric Research, 2022, 91, 621-626.	2.3	16
75	Update in familial Mediterranean fever. Current Opinion in Rheumatology, 2021, 33, 398-402.	4.3	16
76	The clinical course of SARS-CoV-2 infection among children with rheumatic disease under biologic therapy: a retrospective and multicenter study. Rheumatology International, 2022, 42, 469-475.	3.0	16
77	Is Takayasu's arteritis more severe in children?. Clinical and Experimental Rheumatology, 2021, 39, 32-38.	0.8	16
78	The European network for care of children with paediatric rheumatic diseases: care across borders. Rheumatology, 2019, 58, 1188-1195.	1.9	15
79	Performance of the new â€˜Eurofever/PRINTO classification criteriaâ€™ in FMF patients. Seminars in Arthritis and Rheumatism, 2020, 50, 172-175.	3.4	15
80	Frequency of juvenile idiopathic arthritis and associated uveitis in pediatric rheumatology clinics in Turkey: A retrospective study, JUPITER. Pediatric Rheumatology, 2021, 19, 134.	2.1	15
81	Systematic review of childhood-onset polyarteritis nodosa and DADA2. Seminars in Arthritis and Rheumatism, 2021, 51, 559-564.	3.4	14
82	Whole exome sequencing in unclassified autoinflammatory diseases: more monogenic diseases in the pipeline?. Rheumatology, 2021, 60, 607-616.	1.9	13
83	Impact of the COVID-19 pandemic on the frequency of the pediatric rheumatic diseases. Rheumatology International, 2022, 42, 51-57.	3.0	13
84	Performance of Birmingham Vasculitis Activity Score and disease extent index in childhood vasculitides. Clinical and Experimental Rheumatology, 2012, 30, S162-8.	0.8	13
85	Alteration of the microRNA expression profile in familial Mediterranean fever patients. Clinical and Experimental Rheumatology, 2017, 35 Suppl 108, 90-94.	0.8	13
86	Favipiravir use in children with COVID-19 and acute kidney injury: is it safe?. Pediatric Nephrology, 2021, 36, 3771-3776.	1.7	12
87	Pediatric forms of vasculitis. Best Practice and Research in Clinical Rheumatology, 2018, 32, 137-147.	3.3	11
88	The factors affecting the disease course in Kawasaki disease. Rheumatology International, 2019, 39, 1343-1349.	3.0	11
89	Clinical features, muscle biopsy scores, myositis specific antibody profiles and outcome in juvenile dermatomyositis. Seminars in Arthritis and Rheumatism, 2021, 51, 95-100.	3.4	11
90	IgG4-related disease in pediatric patients: a single-center experience. Rheumatology International, 2022, 42, 1177-1185.	3.0	10

#	Article	IF	Citations
91	Update in paediatric vasculitis. Best Practice and Research in Clinical Rheumatology, 2009, 23, 679-688.	3.3	9
92	IgA vasculitis (Henochâ€“SchÃ¶nlein): Case definition andguidelines for data collection, analysis, and presentation of immunisation safety data. Vaccine, 2017, 35, 1559-1566.	3.8	9
93	Recommendations for collaborative paediatric research including biobanking in Europe: a Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) initiative. Annals of the Rheumatic Diseases, 2018, 77, 319-327.	0.9	9
94	The Challenge of Treating Pulmonary Vasculitis in BehÃ§et Disease: Two Pediatric Cases. Pediatrics, 2019, 144, .	2.1	9
95	Polyarteritis nodosa: lessons from 25 years of experience. Clinical and Experimental Rheumatology, 2019, 37 Suppl 117, 52-56.	0.8	9
96	Potential role of pyrin, the protein mutated in familial Mediterranean fever, during inflammatory cell migration. Clinical and Experimental Rheumatology, 2018, 36, 116-124.	0.8	9
97	Vasculitis: do we know more to classify better?. Pediatric Nephrology, 2015, 30, 1425-1432.	1.7	8
98	Assessment of autonomic functions in children with familial Mediterranean fever by using heart rate variability measurements. International Journal of Rheumatic Diseases, 2017, 20, 2086-2092.	1.9	8
99	Whatâ€™s new in autoinflammation?. Pediatric Nephrology, 2019, 34, 2449-2456.	1.7	8
100	Inflammatory milieu of muscle biopsies in juvenile dermatomyositis. Rheumatology International, 2021, 41, 77-85.	3.0	8
101	Recent advances in childhood vasculitis. Current Opinion in Rheumatology, 2017, 29, 530-534.	4.3	8
102	ASAH1 pathogenic variants associated with acid ceramidase deficiency: Farber disease and spinal muscular atrophy with progressive myoclonic epilepsy. Human Mutation, 2020, 41, 1469-1487.	2.5	8
103	Deubiquitination of proteasome subunits by OTULIN regulates type I IFN production. Science Advances, 2021, 7, eabi6794.	10.3	8
104	The role of vascular inflammation markers in deficiency of adenosine deaminase 2. Seminars in Arthritis and Rheumatism, 2021, 51, 839-844.	3.4	7
105	Establishing core domain sets for Chronic Nonbacterial Osteomyelitis (CNO) and Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis (SAPHO): A report from the OMERACT 2020 special interest group. Seminars in Arthritis and Rheumatism, 2021, 51, 957-961.	3.4	7
106	Probiotic use in the prophylaxis of periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome: a retrospective cohort study. Rheumatology International, 2022, , 1.	3.0	7
107	The impact of the Eurofever criteria and the new InFevers MEFV classification in real life: Results from a large international FMF cohort. Seminars in Arthritis and Rheumatism, 2022, 52, 151957.	3.4	7
108	Comparison of patients with familial Mediterranean fever accompanied with sacroiliitis and patients with juvenile spondyloarthropathy. Clinical and Experimental Rheumatology, 2017, 35 Suppl 108, 124-127.	0.8	7

#	Article	IF	Citations
109	Juvenile idiopathic arthritis: lymphocyte activation gene-3 is a central immune receptor in children with oligoarticular subtypes. Pediatric Research, 2021, 90, 744-751.	2.3	6
110	Spinal involvement in juvenile idiopathic arthritis: what do we miss without imaging?. Rheumatology International, 2022, 42, 519-527.	3.0	6
111	Measuring Vasculitis with Numbers: Outcome Scores. Current Rheumatology Reviews, 2020, 16, 21-28.	0.8	6
112	Development of a medication adherence scale for familial Mediterranean fever (MASIF) in a cohort of Turkish children. Clinical and Experimental Rheumatology, 2015, 33, S156-62.	0.8	6
113	The performances of the ILAR, ASAS, and PRINTO classification criteria in ERA patients: a comparison study. Clinical Rheumatology, 2022, 41, 1785-1792.	2.2	5
114	Neutrophil-to-Lymphocyte Ratio: An Easy Marker for the Diagnosis and Monitoring of Inflammatory Bowel Disease in Children. Digestive Diseases and Sciences, 2022, , .	2.3	5
115	The Turkish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 395-402.	3.0	4
116	Concurrence of juvenile idiopathic arthritis and primary demyelinating disease in a young child. Multiple Sclerosis and Related Disorders, 2019, 27, 20-22.	2.0	4
117	Pulmonary Manifestations of Systemic Vasculitis in Children. Pediatric Clinics of North America, 2021, 68, 167-176.	1.8	4
118	Final diagnosis of children and adolescents with musculoskeletal complaints. Minerva Pediatrics, 2017, 69, 50-58.	0.4	4
119	Challenges in diagnosing COVID-19 related disease in pediatric patients with rheumatic disease. Modern Rheumatology, 2022, 32, 1108-1113.	1.8	4
120	Polyarteritis nodosa. Current Opinion in Pediatrics, 2022, 34, 229-233.	2.0	4
121	The invisible part of the iceberg: qualitative aspects of childhood vasculitis. Clinical and Experimental Rheumatology, 2014, 32, S122-7.	0.8	4
122	Treatment of childhood-onset Takayasu arteritis: switching between anti-TNF and anti-IL-6 agents. Rheumatology, 2022, 61, 4885-4891.	1.9	4
123	The challenges in diagnosing pediatric primary antiphospholipid syndrome. Lupus, 2022, 31, 1269-1275.	1.6	4
124	Enalaprilâ€induced anemia in a renal transplant patient. Pediatrics International, 1997, 39, 626-627.	0.5	3
125	Rheumatological manifestations in inborn errors of immunity. Pediatric Research, 2020, 87, 293-299.	2.3	3
126	Plasma checkpoint protein levels and galectin-9 in juvenile systemic lupus erythematosus. Lupus, 2021, 30, 998-1004.	1.6	3

#	Article	IF	Citations
127	Clinical spectrum of children with interstitial pneumonia with autoimmune features. Respiratory Medicine, 2021, 187, 106566.	2.9	3
128	Is Takayasu's arteritis more severe in children?. Clinical and Experimental Rheumatology, 2021, 39 Suppl 129, 32-38.	0.8	3
129	Burden of illness in hereditary periodic fevers: a multinational observational patient diary study. Clinical and Experimental Rheumatology, 2020, 38 Suppl 127, 26-34.	0.8	3
130	Early is superior to late plasma exchange for severe <scp>multisystem inflammatory syndrome in children</scp>. Journal of Clinical Apheresis, 2022, , .	1.3	3
131	Next Generation Sequencing Based Multiplex Long-Range PCR for Routine Genotyping of Autoinflammatory Disorders. Frontiers in Immunology, 2021, 12, 666273.	4.8	2
132	Real-world data on MTX tolerance with regimens used in children versus adults. Clinical Rheumatology, 2021, 40, 5095-5102.	2.2	2
133	Validation of the EULAR/ACR 2017 idiopathic inflammatory myopathy classification criteria in juvenile dermatomyositis patients. Clinical and Experimental Rheumatology, 2021, 39, 688-694.	0.8	2
134	Biologics for immunoglobulin A vasculitis: targeting vasculitis or comorbid disease?. Internal and Emergency Medicine, 2022, 17, 1599-1608.	2.0	2
135	Validation of the EULAR/ACR 2017 idiopathic inflammatory myopathy classification criteria in juvenile dermatomyositis patients. Clinical and Experimental Rheumatology, 2021, 39, 688-694.	0.8	2
136	IgA vasculitis (Henochâ€“SchÃ¶nlein purpura) in children. Expert Opinion on Orphan Drugs, 2017, 5, 405-410.	0.8	1
137	Pediatric Nephrology and Rheumatology Practice Patterns in Granulomatosis with Polyangiitis: A Midwest Pediatric Nephrology Consortium Study. International Journal of Nephrology, 2018, 2018, 1-9.	1.3	1
138	Journey of Vasculitis at Hacettepe University: from the Establishment of University to the Hacettepe AAV Workshop, 2020. Acta Medica, 0, 52, 4-6.	0.2	1
139	Response to: â€˜The country of residence affects the phenotype of familial Mediterranean fever? Is it real or a selection bias?â€™ by Korkmaz. Annals of the Rheumatic Diseases, 2014, 73, e53-e53.	0.9	0
140	A field on the move. Nature Reviews Rheumatology, 2015, 11, 625-626.	8.0	0
141	AB1041â€…PREVALENCE OF JUVENILE IDIOPATHIC ARTHRITIS (JIA) SUBGROUPS AND JIA-ASSOCIATED UVEITIS AMONG JIA PATIENTS ADMITTED TO REFERRAL PEDIATRIC RHEUMATOLOGY CLINICS IN TURKEY: A RETROSPECTIVE STUDY, JUPITER. , 2019, , .		0
142	OP0152â€…OLIGOARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DOES NOT SHOW SIGNS OF T-CELL EXHAUSTION, IN SPITE OF INCREASED EXPRESSION OF CO-INHIBITORY RECEPTORS. , 2019, , .		0
143	A rare cause of steroid-resistant nephrotic syndrome in a child: Answers. Pediatric Nephrology, 2020, 35, 621-623.	1.7	0
144	A rare cause of steroid resistant nephrotic syndrome in a child: Questions. Pediatric Nephrology, 2020, 35, 619-620.	1.7	0

#	Article	IF	Citations
145	Response to: â€˜Correspondence on â€˜Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trialâ€™â€™ by Satiset al. Annals of the Rheumatic Diseases, 2022, 81, e257-e257.	0.9	0
146	Response to letter to the editor. Seminars in Arthritis and Rheumatism, 2020, 50, 1553.	3.4	0
147	FC040: Kidney Transplantation in Childhood-Onset ANCA-Associated Vasculitis: Outcomes in a Multicentre Cohort. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
148	The performance of IgG4-related disease responder index in children. Clinical and Experimental Rheumatology, 0, , .	0.8	0